Gleevec News and Research

RSS
Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
Study shows ABL kinases have enhanced expression and activity in CML

Study shows ABL kinases have enhanced expression and activity in CML

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Cancer-linked mitosis: an interview with Professor Scott Kern, Johns Hopkins University School of Medicine

Scientists prevent cell sleep to reduce chance of tumor recurrence

Scientists prevent cell sleep to reduce chance of tumor recurrence

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

UCLA's Jonsson Comprehensive Cancer Center named one of nation's top 12 cancer centers

New therapeutic targets for infantile myofibromatosis

New therapeutic targets for infantile myofibromatosis

Findings suggest that a prosaposin-based drug could block metastasis spread

Findings suggest that a prosaposin-based drug could block metastasis spread

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Viewpoints: S.C. House race spotlights Dems' discomfort with health law; Cannon, Cohn offer contrasting views of Medicaid study

Viewpoints: S.C. House race spotlights Dems' discomfort with health law; Cannon, Cohn offer contrasting views of Medicaid study

Doctors assail drugmakers for $100K cancer medicines

Doctors assail drugmakers for $100K cancer medicines

MD Anderson professor to receive award for clinical research excellence at AACR meeting

MD Anderson professor to receive award for clinical research excellence at AACR meeting

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Finding solutions to protect U.S. troops against invisible killers

Finding solutions to protect U.S. troops against invisible killers

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Imatinib can relieve and slow down progression of multiple sclerosis

Imatinib can relieve and slow down progression of multiple sclerosis

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

TKI-resistant human leukemia stem cells are the source of genomic instability

TKI-resistant human leukemia stem cells are the source of genomic instability

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves